Compare MHF & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MHF | PMN |
|---|---|---|
| Founded | 1988 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.3M | 131.5M |
| IPO Year | N/A | 2022 |
| Metric | MHF | PMN |
|---|---|---|
| Price | $6.52 | $13.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $42.67 |
| AVG Volume (30 Days) | ★ 59.1K | 31.2K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 4.29% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.63 | $0.29 |
| 52 Week High | $7.64 | $27.40 |
| Indicator | MHF | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 27.23 | 46.88 |
| Support Level | N/A | $12.89 |
| Resistance Level | $7.04 | $14.77 |
| Average True Range (ATR) | 0.08 | 1.22 |
| MACD | -0.02 | -0.13 |
| Stochastic Oscillator | 8.82 | 32.81 |
Western Asset Municipal High Income Fund Inc is a diversified closed-end management investment company. The company's objective is to seek high current income exempt from federal income taxes. It invests predominantly in intermediate and long-term municipal debt securities issued by state and local governments.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.